IMEU is iShares' Irish-domiciled UCITS wrapper around the MSCI Europe index — Europe's developed large- and mid-caps in one fund at 0.12% TER, accumulating. The honest question isn't whether it's a good fund; it's why you'd hold Europe on its own when IWDA and VWCE already carry European stocks.
What's inside
| Ticker | Name | Weight |
|---|---|---|
| ASML | ASML Holding NV | 3.78% |
| AZN | AstraZeneca PLC | 2.27% |
| NVS | Novartis AG | 2.16% |
| HSBC | HSBC Holdings PLC | 2.08% |
| RHHBY | Roche Holding AG | 2.08% |
The top holdings are a roll-call of European blue chips: ASML at 3.78%, then AstraZeneca, Novartis, HSBC, Roche, Shell, Nestlé, TotalEnergies, Siemens, and SAP. The top ten add up to roughly 20% of the basket — far flatter than a US large-cap tracker, where the top ten routinely dominate a third of the index. There is not a single US company in here, which is the whole point of the fund.
Sector-wise it reads like the European economy itself: healthcare (AstraZeneca, Novartis, Roche), financials (HSBC), energy (Shell, TotalEnergies), staples (Nestlé), industrials (Siemens), and exactly one world-class tech name in ASML. That's the structural difference from a US-heavy global fund — no Magnificent Seven doing the heavy lifting, so the whole thing lives or dies on old-economy earnings plus one semiconductor-tool monopoly.
Costs and structure
The ongoing charge is 0.12% — cheap for a regional fund, though a touch above the very cheapest broad-market trackers. On a €50k position that's €60 a year; a rounding error against the regional bet you're actually making.
Replication is optimised physical sampling — iShares holds a representative subset of the MSCI Europe constituents rather than every name, standard for a several-hundred-stock developed-market index.
The fund is Irish-domiciled and accumulating, so dividends — and European equities pay meaningfully more of them than US large-caps — are reinvested inside the wrapper with no cash to redeploy and no tax event until you sell. The base currency is EUR, and because the underlying basket is European-listed there's no meaningful dollar exposure to hedge in the first place; your FX risk is spread across the euro, sterling, and the Swiss franc.
It tracks the MSCI Europe index (provider MSCI), it has run since 25 September 2009, and it holds around €14B in assets. Full detail is on iShares' factsheet.
Performance in context
Live data temporarily unavailable for this comparison.
IMEU against VWCE is the comparison that matters: Europe-only versus a global all-world fund that already holds these same European names as a slice. Whenever European equities lag US-led global indices, IMEU underperforms VWCE by construction — it's missing the US mega-cap engine on purpose. When Europe leads, it's the other way around. Read the chart as the size of the bet you're making, not as a verdict on either fund.
Who buys it and why
IMEU is a deliberate regional tilt, not a one-fund core. If you already own IWDA or VWCE, you already own European stocks at their global market-cap weight — a minority slice, dwarfed by the US. Buying IMEU on top is a bet that Europe is underweighted at that level and deserves more: a home-bias overweight for a Euro investor who wants more of the continent they live and earn in than a global index gives them. If you don't hold that view specifically, you don't need this fund — a single all-world holding already covers Europe. The one honest reason to add it is that you want to lean into European valuations and dividends without going all the way to single stocks.
Alternatives worth knowing
- IWDA — iShares Core MSCI World, developed markets globally. The natural "why not just hold everything" alternative; we put them head to head in IMEU vs IWDA.
- VWCE — Vanguard's FTSE All-World, developed plus emerging in one fund. The broadest single-holding option, with Europe already baked in at market weight.
- ISPA — iShares' STOXX Global Select Dividend 100, if the real draw for you is European-style dividend income rather than the region itself.